News Accession Therapeutics awarded €7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy
News OMass Therapeutics partners with Genentech to Develop and Commercialise Therapies for Inflammatory Bowel Disease